Organovo Holdings Inc  

(Public, NASDAQ:ONVO)   Watch this stock  
Find more results for ONVO
2.97
-0.03 (-1.00%)
After Hours: 2.97 0.00 (0.00%)
Feb 22, 4:00PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.90 - 3.01
52 week 2.00 - 4.99
Open 3.00
Vol / Avg. 1.54M/1.54M
Mkt cap 313.23M
P/E     -
Div/yield     -
EPS -0.38
Shares 104.41M
Beta 1.52
Inst. own 23%
Feb 6, 2017
Q3 2017 Organovo Holdings Inc Earnings Release (Estimated)
Nov 29, 2016
Organovo Holdings Inc at Piper Jaffray Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -832.41% -2601.15%
Operating margin -836.75% -2605.73%
EBITD margin - -2550.78%
Return on average assets -57.50% -63.73%
Return on average equity -62.29% -69.58%
Employees 115 -
CDP Score - -

Address

6275 Nancy Ridge Drive Suite 110
SAN DIEGO, CA 92121
United States - Map
+1-858-5509994 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.

Officers and directors

Keith Murphy Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer and Director
Age: 44
Bio & Compensation  - Reuters
Eric Michael David M.D. J.D. Executive Vice President - Pre-Clinical Development, Chief Strategy Officer
Age: 48
Bio & Compensation  - Reuters
Sharon Collins Presnell Ph.D. Chief Scientific Officer
Age: 47
Bio & Compensation  - Reuters
Jennifer Kinsbruner Bush J.D. Compliance Officer, General Counsel, Corporate Secretary
Age: 41
Bio & Compensation  - Reuters
Paul Gallant General Manager
Age: 51
Bio & Compensation  - Reuters
Robert F. Baltera Jr. Lead Independent Director
Age: 51
Bio & Compensation  - Reuters
James T. Glover Independent Director
Age: 66
Bio & Compensation  - Reuters
Richard A. Heyman Ph.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Tamar D. Howson Independent Director
Age: 68
Bio & Compensation  - Reuters
Kirk Malloy Ph.D. Independent Director
Age: 49
Bio & Compensation  - Reuters